再生医療の世界市場（2025年～2032年）

世界の再生医療の市場規模は、2024年に484億5,000万米ドルに達し、2032年には2,132億7,000万米ドルに達すると予測され、予測期間2025年～2032年のCAGRは18.7%で成長する見通しです。

再生医療は、正常な機能を回復または確立するために、ヒトの細胞、組織、または臓器を置換または再生するプロセスと定義されます。その目的は、単に薬や処置によって症状を管理するのではなく、損傷した組織や臓器を治癒または置換することです。この分野には、身体の自然治癒メカニズムを活用する様々なアプローチが含まれます。

この革新的な分野では、組織工学、細胞療法、医療機器や人工臓器の開発など、さまざまなツールや技術が活用されています。 これらのアプローチを組み合わせることで、再生医療は、最も必要とされる場所で身体の自然治癒プロセスを増幅させたり、永久に損傷した臓器の機能を引き受けたりすることができます。研究者たちは、一般的に自然治癒が難しい組織の再生を刺激する方法を模索しています。

この分野には、生物学、化学、コンピューター科学、工学、遺伝学、医学、ロボット工学など、さまざまな分野の専門家が集まっています。人類が直面する最も困難な医療課題に対する包括的な解決策を開発するためには、このような協力体制が不可欠です。このような要因が、世界の再生医療市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

技術の進歩

技術の進歩は、世界の再生医療市場の成長の重要な促進要因であり、その進化と能力の拡大に大きな影響を与えています。この分野は、再生療法の有効性と応用を強化する技術革新に後押しされ、急速に進歩しています。

幹細胞研究、特に人工多能性幹細胞（iPSC）の開発における革新は、再生医療の潜在的な応用範囲を広げています。iPSCは成体細胞から生成することができ、様々な細胞型に分化する能力を持っているため、治療目的には非常に貴重です。

CRISPR/Cas9のような技術は、DNAの正確な改変を可能にし、遺伝子治療を一変させました。この能力は、遺伝性疾患の標的治療を可能にし、再生治療の効果を高めます。医薬品開発や臨床試験にAIを取り入れることで、プロセスが合理化され、データ分析が強化され、患者の転帰が改善されます。ハイテク企業とバイオテクノロジー企業のコラボレーションは、新治療法の市場投入までの時間を短縮すると同時に、その効果を最大化することを目指しています。

さらに、パートナーシップやコラボレーション、革新的な発売などの主要企業の戦略は、この世界の再生医療市場の成長を促進すると思われます。例えば、2024年10月、南カリフォルニア大学（USC）は、Charles Murry博士が設立したバイオテクノロジー企業であるStemCardiaと、心臓再生に焦点を当てた治療法を推進するための戦略的提携を発表しました。この提携は、世界の死因の上位を占め、ヘルスケアシステムに大きな負担を強いている心不全に対する革新的な治療法の必要性に取り組むことを目的としています。

また、2024年8月、メソ・ニューミマティクスは、再生医療技術グループとして再ブランド化を進めています。メソ・ニューミマティクスは、Global Stem Cells Group（GSCG）による革新的なペプチドラインの発売を発表することに意欲的でした。Cellgenicと呼ばれるこの新ラインは、再生医療の分野で医師向けに特別にデザインされた先進的な製品や機器を普及・販売するGSCGの継続的な取り組みの一環です。Cellgenicは、この取り組みを通じて、患者ケアと治療成果を高める最先端のソリューションを医療従事者に提供することを目指しています。

同様に、マウントサイナイは2023年4月、白血病、アルツハイマー病、乳がん、呼吸器疾患など、さまざまな疾患に対する研究と治療法の選択肢を強化することを目的とした革新的なイニシアチブであるInstitute for Regenerative Medicineを立ち上げました。この研究所は、マウントサイナイのアイカーン医科大学内の様々な部門にまたがる研究努力を統合・調整し、再生医療のリーダーとしての地位を確立することを目的としています。これらすべての要因が、世界の再生医療市場に需要をもたらしています。

さらに、細胞療法や遺伝子治療に対する需要の高まりも、世界の再生医療市場の拡大に寄与しています。

高い治療費

治療費の高騰は再生医療の世界市場の大きな抑制要因であり、患者のアクセスや市場全体の成長に影響を与えています。

再生医療治療法の開発には、広範な研究、臨床試験、規制遵守が必要であり、これらすべてに多額の財政投資が伴います。これらの高い研究開発費はしばしば患者に転嫁され、結果として高額な治療となります。DVCの幹細胞データによると、幹細胞療法の費用は、使用される幹細胞の種類、投与される細胞の数、それらの細胞の質、治療施設の場所、幹細胞の供給源など、いくつかの要因によって大きく異なります。平均して、患者は幹細胞療法に5,000米ドル～5万米ドルを支払うと予想されます。

一回の注射にかかる費用は、通常約4,000米ドルです。多血小板血漿（PRP）を使用して、同じセッション中に追加の関節や怪我を治療する場合は、それぞれ800米ドル程度で対応できます。2023年には、拡大細胞製剤を用いた幹細胞療法の最も一般的な価格は、1万5,000米ドルから3万米ドルの間でした。これは、臨床現場においてこれらの治療法が受け入れられ、需要が高まっていることを反映しています。

再生医療、特に幹細胞や複雑な生物学的材料を用いた再生医療は、複雑でコストがかかります。高度な製造技術、厳格な品質管理対策、専門施設の必要性などが、全体的な費用の一因となっています。したがって、上記の要因が世界の再生医療市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 技術進歩
  • 抑制要因
    • 高額な治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• 細胞療法
• 幹細胞療法
  • 自家移植
  • 同種療法
• 細胞ベースの免疫療法製品
• 遺伝子治療
• 組織工学
• 多血小板血漿（PRP）療法
• プロロセラピー
• その他

第7章 用途別

• 腫瘍学
• 心血管疾患
• 神経学
• 眼科
• 免疫学と炎症
• 皮膚科・創傷ケア
• 筋骨格障害
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Amgen Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 実績および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Novartis AG
• Gilead Sciences, Inc.（Kite Pharma, Inc.）
• F. Hoffmann-La Roche Ltd
• Integra LifeSciences Corporation.
• Astellas Pharma Inc.
• Bayer AG
• Pfizer Inc.
• Vericel Corporation
• MIMEDX Group, Inc.
• Biogen Inc.
• Sarepta Therapeutics, Inc.
• Smith+Nephew
• MEDIPOST

第11章 付録

The global regenerative medicine market reached US$ 48.45 billion in 2024 and is expected to reach US$ 213.27 billion by 2032, growing at a CAGR of 18.7 % during the forecast period 2025-2032.

Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues, or organs to restore or establish normal function. Its goal is to heal or replace damaged tissues and organs rather than merely managing symptoms with medications or procedures. This field encompasses a range of approaches that leverage the body's natural healing mechanisms.

This innovative field utilizes various tools and techniques, including tissue engineering, cellular therapies, and the development of medical devices and artificial organs. Techniques and tools used in regenerative medicine are tissue engineering, cellular therapies, medical devices, and artificial organs. By combining these approaches, regenerative medicine can amplify the body's natural healing processes where they are most needed or assume the function of permanently damaged organs. Researchers are exploring ways to stimulate the regeneration of tissues that typically do not heal well on their own.

The field brings together experts from diverse disciplines such as biology, chemistry, computer science, engineering, genetics, medicine, and robotics. This collaboration is essential for developing comprehensive solutions to some of the most challenging medical problems faced by humanity. These factors have driven the global regenerative medicine market expansion.

Market Dynamics: Drivers & Restraints

Advancements in Technology

Advancements in technology are a crucial driver of growth in the global regenerative medicine market, significantly influencing its evolution and expanding its capabilities. This sector is rapidly progressing, propelled by innovations that enhance the effectiveness and application of regenerative therapies.

Innovations in stem cell research, particularly the development of induced pluripotent stem cells (iPSCs), have broadened the potential applications of regenerative medicine. iPSCs can be generated from adult cells and possess the ability to differentiate into various cell types, making them invaluable for therapeutic purposes.

Technologies such as CRISPR/Cas9 have transformed gene therapy by enabling precise modifications to DNA. This capability allows for targeted treatments for genetic disorders and enhances the effectiveness of regenerative therapies. The incorporation of AI in drug development and clinical trials streamlines processes, enhances data analysis, and improves patient outcomes. Collaborations between tech companies and biotech firms aim to shorten the time-to-market for new therapies while maximizing their effectiveness.

Furthermore, key player strategies such as partnerships & collaborations, and innovative launches would propel this global regenerative medicine market growth. For instance, in October 2024, the University of Southern California (USC) announced a strategic collaboration with StemCardia, a biotechnology company founded by Dr. Charles Murry, to advance therapies focused on heart regeneration. This partnership aims to tackle the critical need for innovative treatments for heart failure, which is the leading cause of death worldwide and poses a significant burden on healthcare systems.

Also, in August 2024, Meso Numismatics, Inc. ("Meso Numismatics" or the "Company") is in the process of rebranding itself as Regenerative Medical Technology Group. The Company is excited to announce the launch of an innovative peptide line by Global Stem Cells Group (GSCG). This new line, called Cellgenic, is part of GSCG's ongoing efforts to promote and distribute advanced products and equipment specifically designed for physicians in the field of regenerative medicine. Through this initiative, Cellgenic aims to provide healthcare professionals with cutting-edge solutions that enhance patient care and treatment outcomes.

Similarly, in April 2023, Mount Sinai launched the Institute for Regenerative Medicine, an innovative initiative designed to enhance research and treatment options for a variety of diseases, including leukemia, Alzheimer's disease, breast cancer, and respiratory disorders. This institute aims to integrate and coordinate research efforts across various departments within the Icahn School of Medicine at Mount Sinai, establishing the institution as a leader in regenerative medicine. All these factors demand the global regenerative medicine market.

Moreover, the rising demand for cell and gene therapies contributes to the global regenerative medicine market expansion.

High Treatment Costs

High treatment costs are a significant restraint in the global regenerative medicine market, impacting patient access and overall market growth.

The development of regenerative medicine therapies requires extensive research, clinical trials, and regulatory compliance, all of which involve substantial financial investment. These high R&D costs are often passed on to patients, resulting in expensive treatments. As per DVC stem data stated that the cost of stem cell therapy can vary significantly based on several factors, including the type of stem cells used, the number of cells administered, the quality of those cells, the location of the treatment facility, and the source of the stem cells. On average, patients can expect to pay between $5,000 and $50,000 for stem cell therapy.

A single injection typically costs around $4,000. If additional joints or injuries are treated during the same session using Platelet Rich Plasma (PRP), these can be addressed for as little as $800 each. In 2023, the most common price for stem cell therapy utilizing an expanded cell product ranged between $15,000 and $30,000. This reflects the growing acceptance and demand for these therapies in clinical practice.

Producing regenerative therapies, particularly those involving stem cells or complex biological materials, is intricate and costly. Advanced manufacturing techniques, stringent quality control measures, and the need for specialized facilities contribute to the overall expenses. Thus, the above factors could be limiting the global regenerative medicine market's potential growth.

For more details on this report - Request for Sample

Segment Analysis

The global regenerative medicine market is segmented based on product type, application, and region.

Product Type:

The cell therapy segment is expected to dominate the global regenerative medicine market share

The cell therapy segment holds a major portion of the global regenerative medicine market share and is expected to continue to hold a significant portion of the global regenerative medicine market share during the forecast period.

The rising incidence of long-term conditions such as cancer, autoimmune diseases, and cardiovascular ailments has led to greater adoption of cell therapies. According to the CDC, about 60% of adults in the U.S. have at least one chronic condition, highlighting the demand for effective treatment options.

Innovations in cell therapy, including stem cell therapy and cell-based immunotherapies, are enhancing treatment efficacy. These therapies involve replacing damaged tissues with healthy cells or stimulating tissue repair and regeneration. Cell therapies often utilize autologous cells (derived from the patient), which minimizes the risk of rejection and side effects while providing tailored treatment options based on individual patient needs.

Significant investments in R&D for cell therapies are leading to discoveries and improved treatment methodologies. Funding initiatives aimed at developing cell-based immunotherapies are gaining traction, further propelling market growth.

Furthermore, key players in the industry key initiatives, and expansion would propel this segment's growth in the the global regenerative medicine market. For instance, in December 2024, Sumitomo Chemical and Sumitomo Pharma announced the formation of a joint venture called RACTHERA Co., Ltd., aimed at advancing research and development in regenerative medicine and cell therapy. This initiative represents a strategic effort to enhance the capabilities of both companies within the rapidly expanding market for regenerative therapies.

Also, in October 2023, Bayer AG inaugurated its first Cell Therapy launch Facility in Berkeley, California, marking a significant advancement in the company's ability to produce cell therapies on a global scale. This state-of-the-art facility represents a substantial investment of $250 million and covers an area of 100,000 square feet. It is designed to supply essential materials for late-stage clinical trials and the potential commercial launch of bemdaneprocel (BRT-DA01), an investigational cell therapy currently under evaluation for treating Parkinson's disease. These factors have solidified the segment's position in the global regenerative medicine market.

Geographical Analysis

North America is expected to hold a significant position in the global regenerative medicine market share

North America holds a substantial position in the global regenerative medicine market and is expected to hold most of the market share.

The increasing incidence of long-term conditions such as cancer, cardiovascular diseases, and autoimmune disorders has led to a greater demand for effective regenerative therapies. According to the CDC, around 60% of adults in the U.S. have at least one chronic condition, emphasizing the need for innovative treatment options.

North America is home to numerous research institutions and biotechnology companies that are at the forefront of regenerative medicine. Significant R&D investments are fueling advancements in cell therapies, gene therapies, and tissue engineering. The presence of supportive regulatory frameworks allows for faster approval processes for new therapies. The number of clinical trials has surged, with 394 trials reported during the third quarter of 2023, demonstrating active engagement from key players in developing and testing new regenerative treatments.

Major pharmaceutical and biotech companies are heavily investing in regenerative medicine initiatives within North America. For instance, Pfizer's recent investment in cell therapy development reflects growing interest from industry leaders to expand their capabilities in this area. North America benefits from a well-established healthcare system with advanced technological frameworks that facilitate rapid diagnosis and treatment of chronic diseases. High healthcare spending further supports the adoption of innovative therapies.

The trend towards personalized medicine, where treatments are tailored to individual patient needs, is particularly strong in North America. Cell therapies often utilize autologous cells (derived from the patient), which reduces the risk of rejection and improves treatment outcomes. Furthermore, key players in the industry product launches and approvals that would drive this regenerative medicine market growth.

For instance, in September 2024, Poseida Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational therapy, P-BCMA-ALLO1. This allogeneic CAR-T cell treatment, which utilizes stem cell memory T cells (TSCM), is currently undergoing Phase 1/1b clinical development aimed at treating patients with relapsed/refractory multiple myeloma, a challenging form of blood cancer.

Thus, the above factors are consolidating the region's position as a dominant force in the global regenerative medicine market.

Asia Pacific is growing at the fastest pace in the global regenerative medicine market share

Asia Pacific holds the fastest pace in the global regenerative medicine market and is expected to hold most of the market share.

The prevalence of chronic conditions such as diabetes, cardiovascular diseases, and neurodegenerative disorders is on the rise in the Asia Pacific region. This trend increases the demand for innovative treatments that regenerative medicine can provide. The Asia Pacific region has seen a surge in healthcare expenditure, driven by both government initiatives and private investments. Countries like China, India, and Japan are significantly increasing their healthcare budgets to improve access to advanced medical technologies, including regenerative medicine.

The region is home to a vast and growing patient population that is increasingly seeking affordable and effective treatment options for chronic diseases, injuries, and degenerative conditions. This demand fuels the adoption of regenerative therapies. Many governments in the Asia Pacific are actively promoting regenerative medicine through favorable policies and funding for research and development. For instance, Japan's Regenerative Medicine Act encourages the clinical development of cell-based therapies, while South Korea's legislation supports advanced regenerative medical products.

Rapid advancements in stem cell technology, gene therapy, and tissue engineering are driving innovation in the field. Companies are increasingly investing in R&D to develop new therapies that can effectively address various health issues.

Furthermore, key players in the industry product launches that would drive this global regenerative medicine market growth. For instance, in July 2024, Bioserve India launched its advanced stem cell products, representing a significant advancement in the Indian regenerative medicine sector. This initiative, developed in collaboration with REPROCELL, aims to drive innovation in scientific research and drug development, thereby enhancing progress in regenerative medicine and therapeutic discovery within the Indian market.

Also, in September 2024, Aurion Biotech announced the commercial launch of Vyznova (generic name: neltependocel) in Japan, marking a significant advancement in the treatment of bullous keratopathy of the cornea. This therapy is recognized as the first approved cell therapy specifically designed for corneal endothelial diseases and has successfully received both regulatory and reimbursement approvals in Japan.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global regenerative medicine market.

Competitive Landscape

The major global players in the regenerative medicine market include Amgen Inc., Novartis AG, Gilead Sciences, Inc. (Kite Pharma, Inc.), F. Hoffmann-La Roche Ltd, Integra LifeSciences Corporation., Astellas Pharma Inc., Bayer AG, Pfizer Inc., Vericel Corporation, MIMEDX Group, Inc., Biogen Inc., Sarepta Therapeutics, Inc., Smith+Nephew, and MEDIPOST among others.

Key Developments

• In January 2025, CellSave Arabia announced the launch of adult stem cell banking services, expanding its offerings beyond its established newborn stem cell preservation. As a leader in stem cell storage, CellSave Arabia is dedicated to providing a forward-thinking approach to personal health by safeguarding individuals' well-being through advanced stem cell preservation techniques.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global regenerative medicine market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in Technology
  • 4.1.2. Restraints
    • 4.1.2.1. High Treatment Costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Cell Therapy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Stem Cell Therapy
  • 6.3.1. Autologous
  • 6.3.2. Allogenic Therapies
• 6.4. Cell-based Immunotherapy Products
• 6.5. Gene Therapy
• 6.6. Tissue Engineering
• 6.7. Platelet-Rich Plasma (PRP) Therapy
• 6.8. Prolotherapy
• 6.9. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Oncology*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Cardiovascular Diseases
• 7.4. Neurology
• 7.5. Ophthalmology
• 7.6. Immunology & Inflammation
• 7.7. Dermatology & Wound Care
• 7.8. Musculoskeletal Disorders
• 7.9. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

• 10.1. Amgen Inc. *
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals etc.
  • 10.1.5. SWOT Analysis
• 10.2. Novartis AG
• 10.3. Gilead Sciences, Inc. (Kite Pharma, Inc.)
• 10.4. F. Hoffmann-La Roche Ltd
• 10.5. Integra LifeSciences Corporation.
• 10.6. Astellas Pharma Inc.
• 10.7. Bayer AG
• 10.8. Pfizer Inc.
• 10.9. Vericel Corporation
• 10.10. MIMEDX Group, Inc.
• 10.11. Biogen Inc.
• 10.12. Sarepta Therapeutics, Inc.
• 10.13. Smith+Nephew
• 10.14. MEDIPOST

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us